Entecavir

CLINICAL USE

Treatment of chronic hepatitis B infection

DOSE IN NORMAL RENAL FUNCTION

500 mcg daily; 1000 mcg daily in lamivudine-refractory patients

PHARMACOKINETICS

  • Molecular weight                           :295.3
  • %Protein binding                           :13
  • %Excreted unchanged in urine     : 75
  • Volume of distribution (L/kg)       :Large
  • half-life – normal/ESRD (hrs)      :128–149

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

    30–50 250 mcg daily; 500 mcg daily in lamivudine-refractory patients10–30 150 mcg daily; 300 mcg daily in lamivudine-refractory patients

  • <10           : 50 mcg daily; 100 mcg daily in lamivudine-refractory patients

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD                :0.3% dialysed. Dose as in GFR <10 mL/min
  • HD                     :13% dialysed. Dose as in GFR <10 mL/min
  • HDF/high flux   :Dialysed. Dose as in GFR
  • <10           : mL/min
  • CAV/VVHD      :Likely to be dialysed. Dose as in GFR=10–30 mL/min

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugs

  • None known

    ADMINISTRATION

    Reconstition

    –

    Route

    Oral

    Rate of Administration

    –

    Comments

    –

    • Tags:

    Related News

    ffddfd

    Hyperlipidemia